We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The House Energy and Commerce Committee is asking five drugmakers to provide information about their plans to prevent or reduce drug counterfeiting, the diversion of their products from the legitimate supply chain and the sale of their drugs by illicit internet sites and foreign pharmacies.
With cracking down on the trafficking of counterfeit drugs a major priority, FDA will be hard pressed to finally implement the repeatedly stayed final paper pedigree rule this April and burden small distributors with the task of proving the source of their goods.
Drug distributors should be required to document where a drug product has come from and where it is going to at least one step in the distrubution chain until electronic track and trace technologies can be developed and adopted by the industry, Johnson & Johnson (J&J) told the FDA recently.
The U.S. drug supply chain should adopt a “one step forward, one step back” model of documenting drug products until electronic track and trace technologies can be developed and adopted by the industry, Johnson & Johnson (J&J) told the FDA.
Facing increasing pressure from drug manufacturers to limit the flow of counterfeit drugs, the FDA may have to finally implement the repeatedly stayed final paper pedigree rule this April and burden small distributors with the task of proving the source of their goods.
Roche is cautioning physicians not to prescribe its popular flu treatment to patients under a year old following recent animal safety trial results, according to a letter released on the FDA’s MedWatch website late Friday.
Wholesalers and distributors who do not comply with new supply chain requirements issued by Pfizer will be left out in the cold when it comes to trafficking the drug giant’s products, the firm announced late December.
With New York State chiming in as the most recent government to consider the reimportation of drugs from Canada as a cost savings measure, Canadian pharmacists are taking a stand against U.S. state and local governments’ assumptions that their country’s price-controlled drug supply is America’s discount mail-order pharmacy.
In its first challenge to ban the sale of a dietary supplement under the 1994 Dietary Supplement Health and Education Act (DSHEA), FDA announced Tuesday it will issue a final rule to prohibit the sale of dietary supplements containing ephedra.